Google’s cloud business is growing fast and turning more profitable, while YouTube Shorts starts to earn like regular videos—setting up new ways to make money from ads and creators. The big question is whether heavy spending on new tech like Gemini and other bets pays off enough to keep this momentum going.Read more

Proximus has spent heavily to upgrade its network and buy new businesses, and that shift has pushed income-focused shareholders to the exits. If those investments start paying off and new competition stays weaker than feared, the company could look very different a few years from now.Read more

Brambles quietly keeps global supply chains moving by renting out reusable pallets and containers to everyday industries like supermarkets, medicine, and farming. Its steady, repeat-customer model and sustainability angle look built for durability, but rising costs and new logistics rivals could still bite.Read more

A Precision Approach to Hard-to-Treat Cancers RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment.Read more

Capstone turns a former biotech shell into a roll-up business selling stone veneer and masonry supplies, aiming to stitch together many small regional distributors into a larger, national platform. New in-house product lines, expansion into new regions, and a cleaner cost base could lift profitability—but it depends on pulling off acquisitions without overreaching in a construction market that can cool quickly.Read more

Silo Pharma is betting on a mix of familiar medicines and psychedelic-inspired science to tackle conditions like PTSD, chronic pain, Alzheimer’s, and multiple sclerosis—using novel delivery methods like nasal sprays and tiny implants. The big question is whether its early test results and research partners can translate into human trials before funding needs and regulatory hurdles slow things down.Read more

Saudi Aramco may look like a dull oil giant, but its steady cash payouts and government backing make it feel more like a “bond-plus” that could still grow over time. The bigger story is how it could use its scale and Saudi Arabia’s long-term plans to stay relevant as the world shifts toward cleaner energy—while geopolitics remains the key thing that could derail the ride.Read more

PVA TePla has been hit hard by a slump in chips tied to electric vehicles and clean energy, but it’s betting on a rebound with a new factory and a plan to grow much bigger over the next few years. If demand for its chip-making and materials equipment turns up again—especially around silicon carbide—this could look very different, though a slow recovery remains the big catch.Read more

CSL Limited: Fair Value Assessment Amidst Evolving US Tariff Scenarios Executive Summary This report provides an assessment of the fair value of CSL Limited (CSL) under various potential United States (US) tariff scenarios. CSL, a global biotechnology leader with significant operations in plasma therapies (CSL Behring), influenza vaccines (CSL Seqirus), and iron/nephrology treatments (CSL Vifor), faces potential impacts from evolving US trade policies.Read more